NASDAQ : DRUG
Bright Minds Biosciences Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 54.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 544.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 544.36M |
| Enterprise Value | 323.78M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.86M |
| Shares Outstanding | 9.86M |
| Shares Change (YoY) | +38.94% |
| Shares Change (QoQ) | +2.51% |
| Owned by Insiders (%) | 11.41% |
| Owned by Institutions (%) | 74.71% |
| Float | 6.74M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.51 |
| P/TBV Ratio | 2.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 121.97 |
| Quick Ratio | 121.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -753.50 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -13.63% |
| Return on Assets (ROA) | -13.50% |
| Return on Invested Capital (ROIC) | -13.61% |
| Return on Capital Employed (ROCE) | -12.73% |
| Weighted Average Cost of Capital (WACC) | 5.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$663,789 |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -52.26% |
| 50-Day Moving Average | 58.16 |
| 200-Day Moving Average | 72.95 |
| Relative Strength Index (RSI) | 22.73 |
| Average Volume (20 Days) | 230,555 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 829,718 |
| Short Previous Month | 882,832 |
| Short % of Shares Out | 8.41% |
| Short % of Float | 12.32% |
| Short Ratio (days to cover) | 5.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.59M |
| Pretax Income | -17.26M |
| Net Income | -17.26M |
| EBITDA | n/a |
| EBIT | -27.59M |
| Earnings Per Share (EPS) | -$2.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 216.77M |
| Total Debt | 46,186 |
| Net Cash | 216.72M |
| Net Cash Per Share | $21.97 |
| Equity (Book Value) | 216.74M |
| Book Value Per Share | 21.97 |
| Working Capital | 216.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -17.67M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 54,464 |
| Net Borrowing | -75,026 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.94% |
| Shareholder Yield | -38.94% |
| Earnings Yield | -7.81% |
| FCF Yield | n/a |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $154.70 |
| Price Target Difference | 490.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |